

## Board of Directors Meeting in Public - Cover Sheet

<b>Subject:</b>	Research and Development Quarterly Update		<b>Date: 30<sup>th</sup> August 2018</b>	
<b>Prepared By:</b>	Alison Steel, Research and Innovation Manager			
<b>Approved By:</b>	David Hodgson, Research and Innovation Director			
<b>Presented By:</b>	David Hodgson, Research and Innovation Director			
<b>Purpose</b>				
<ul style="list-style-type: none"> <li>Q1 summary of R&amp;I metrics and benchmarking against 2017/18 performance</li> <li>Assurance of financial position at Q1 and update on 2018/19 confirmed budget</li> <li>Workforce update</li> <li>Outline of 2018-2019 Strategic priorities</li> </ul>			<b>Approval</b>	
			<b>Assurance</b>	X
			<b>Update</b>	
			<b>Consider</b>	
<b>Strategic Objectives</b>				
<b>To provide outstanding care to our patients</b>	<b>To support each other to do a great job</b>	<b>To inspire excellence</b>	<b>To get the most from our resources</b>	<b>To play a leading role in transforming health and care services</b>
X		X	X	X
<b>Overall Level of Assurance</b>				
	<b>Significant</b>	<b>Sufficient</b>	<b>Limited</b>	<b>None</b>
		X		
<b>Risks/Issues</b>				
<b>Financial</b>	<ul style="list-style-type: none"> <li>Reduction in EMCRN budget by 2.3% 2018/19</li> <li>Business case for Clinical Research Facility not successful which may impede growth of the commercial research portfolio. Trust commitment to facility development in the strategy</li> <li>Loss of ability to increase of EMCRN budget year on year due to risks of portfolio imbalance linked to lack of ability to conduct more interventional trials</li> <li>Inability to build research capacity and capability over the next several years and develop the R&amp;I business model if income generated from commercial trials is not directly used towards supporting R&amp;I growth</li> </ul>			
<b>Patient Impact</b>	Decreased opportunity for our patient population to take part in research and access new and novel treatments, and increase quality of patient care at SFH			
<b>Staff Impact</b>	Creative use of funding in developing new research secondments and working together with Senior nurse leaders to develop Nurse Research Academy			
<b>Services</b>				
<b>Reputational</b>	Currently have a strong reputation for research delivery across the region and have been praised for strengths in financial probity, overall recruitment and recruitment to time and target by the EMCRN. Risk this may be affected if research portfolio and complexity remains static.			
<b>Committees/groups where this item has been presented before</b>				
None				
<b>Executive Summary</b>				
<p>Recruitment performance in Research and Innovation at SFH continues to increase. Q1 performance 2018-19:</p> <ul style="list-style-type: none"> <li>843 participants recruited in 18/19 c.f to 297 in 17/18, 65% increase</li> <li>On track to meet and exceed target of 1400 recruits by Q4 18/19</li> <li>78 studies are open at SFH with 35 actively recruiting</li> </ul>				

- 100% of commercial and 74% of non-commercial studies are recruiting to 100% time and target
- Trials are spread across most specialities in the organisation with more clinical research activity being conducted in the areas of Cancer, Cardiovascular disease, Gastroenterology, Reproductive Health and Childbirth and Stroke.
- Charts 1-4 provide visual performance data
- Chart 5 provides complexity weighting for 17/18 recruitment

Research activity in the organisation is increasing year on year, giving more patients the opportunity to participate in studies allowing them access to novel treatments and interventions.

Commercial pharmaceutical and medical device research is also growing at SFH creating an excellent reputation for delivery with commercial sponsors, subsequently attracting new and renewed business. SFH is now being supported as a priority growth area by East Midlands Clinical Research Network.

Research and Innovation is meeting all its contractual obligations and reports quarterly to the Department of Health on “Performance and Initiation in Clinical Research” metrics which are publicly available. Currently joint 1<sup>st</sup> in the league tables for initiating trials.

R&I received a 2.3% budget decrease (£714,137.55) 2018/19 but high performance last year will not influence budgets until 2019/20.

2018/19 Strategic priorities:

1. Broadening the SFH research portfolio in order to support service delivery and innovative practices
2. Growth of commercial research activity through collaboration with EMCRN
3. Improving and contributing to the quality agenda through creating more research opportunities for patients and staff

The service we provide continues to deliver better outcomes for patients, allowing them access to new and different treatments. The reputation of the Research and Innovation department and SFH as a research active organisation continues to grow. We have strong associations with other NHS Trusts and Universities and are committed to expanding the research activity, breadth of our portfolio and facilities at SFH through delivering our research strategy.

Studies show at a local level research can have positive outcomes in terms of increased quality of care, patient satisfaction and financial benefits to the organisation. It is well known that organisations that are research active provide better care to their patients and have better outcomes. It is important as a research active organisation that wherever possible we continue to make the changes and meet the requirements needed to advance our research activity and build research capacity for the future.